Education
About Us
Working with TipRanks
Follow Us
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
9989 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$2.73 - HK$5.92
Previous CloseN/A
Volume172.00K
Average Volume (3M)3.03M
Market Cap
HK$15.78B
Enterprise ValueHK$6.92B
Total Cash (Recent Filing)¥2.12B
Total Debt (Recent Filing)¥4.92B
Price to Earnings (P/E)9.3
Beta0.91
Next Earnings
Apr 25, 2025EPS Estimate
0.11Next Dividend Ex-Date
May 26, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding220,094,500
10 Day Avg. Volume3,843,350
30 Day Avg. Volume3,033,650
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)69.73
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.88Price Target Upside-10.60% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
---
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H News
PremiumCompany Announcements
Shenzhen Hepalink Schedules Board Meeting for Q1 Results
PremiumCompany Announcements
Shenzhen Hepalink Announces Changes in Nomination Committee
PremiumCompany Announcements
Shenzhen Hepalink Announces Board of Directors and Committee Roles
PremiumCompany Announcements
Shenzhen Hepalink Announces Final Dividend for 2024
PremiumCompany Announcements
Shenzhen Hepalink Reports Strong Profit Recovery in 2024 Annual ResultsPremiumCompany Announcements
Shenzhen Hepalink to Approve Annual Results and Consider Dividend
PremiumCompany Announcements
Shenzhen Hepalink Receives Approval for Clinical Trial of New Cancer Drug---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.36%
Mutual Funds
― Other Institutional Investors
99.31% Public Companies and
Individual Investors
9989 FAQ
What was Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price range in the past 12 months?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H lowest stock price was HK$2.73 and its highest was HK$5.92 in the past 12 months.
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap is HK$15.78B.
When is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date is Apr 25, 2025 which is in 9 days.
How were Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s earnings last quarter?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H released its earnings results on Mar 28, 2025. The company reported -HK$0.096 earnings per share for the quarter, beating the consensus estimate of -HK$0.118 by HK$0.022.
Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pay dividends?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays a Notavailable dividend of HK$0.267 which represents an annual dividend yield of N/A. See more information on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H dividends here
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate is 0.11.
How many shares outstanding does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H have?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding.
What happened to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price movement after its last earnings report?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H reported an EPS of -HK$0.096 in its last earnings report, beating expectations of -HK$0.118. Following the earnings report the stock price went down -1.293%.
Which hedge fund is a major shareholder of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9989
---
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
HK$3.88 (-10.60% Downside)
HK$3.88 (-10.60% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.00%
12-Months-Change
Fundamentals
Return on Equity
5.38%
Trailing 12-Months
Asset Growth
-11.72%
Trailing 12-Months
Company Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) is a leading global pharmaceutical company headquartered in Shenzhen, China. The company operates primarily in the biopharmaceutical sector and specializes in the research, development, production, and commercialization of heparin and heparin-related products. Hepalink's product portfolio includes active pharmaceutical ingredients (APIs), finished dosage forms, and biologics, catering to a wide range of therapeutic areas such as anticoagulation, oncology, and cardiovascular diseases.
---
9989 Stock 12 Month Forecast
Average Price Target
HK$3.88
▼(-10.60% Downside)
Technical Analysis
Shanghai Fosun Pharmaceutical (Group) Co
―
Livzon Pharmaceutical Group
―
China Medical System Holdings
―
Best Analysts Covering 9989
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
-5.90%
reiterated a sell rating 13 days ago
Copying Ziyi Chen's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -5.90% per trade.
---